Daflon

Daflon is a micronized purified flavonoid fraction containing 90% diosmin and 10% other flavonoids expressed as hesperidin. It is manufactured by Laboratoires Servier.[1]

Vein diseases and hemorrhoids

Because Daflon is not an FDA-approved medication, it cannot be advertised for treatment of diseases in the United States. Daflon is under preliminary research for its potential use in treating vein diseases,[2] or hemorrhoids.[3] It is sold as a drug in France[4][5] and Malaysia.[6][7]

A 2020 Cochrane review on phlebotonics, including Diosmin showed moderate certainty evidence for slightly reducing oedema compared to placebo in the treatment of chronic venous insufficiency.[8] Furthermore, this same review found moderate quality evidence for little to no difference in quality of life and low certainty evidence that this class of drugs do not influence ulcer healing.[8] Diosmiplex, a micronized purified flavonoid fraction, with similar venous insufficiency indication, is sold as a prescription medical food in the US.[9]

Dosage

For venous insufficiency, the dosage is 2 tablets daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily for 4 days, followed by 4 tablets daily over the next 3 days.[10] For chronic venous disease, the dosage is 2 tablets a day for at least 2 months.[11]

Side effects

Possible side effects include routine gastric disorders and neurovegetative disorders.

References
  1. "Offocial Monograph. Daflon 500: Summary of Product Characteristics" (PDF). www.servier.com.ve. Archived (PDF) from the original on 2016-12-28. Retrieved 2018-12-09.
  2. Lyseng-Williamson KA, Perry CM (2003). "Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids". Drugs. 63 (1): 71–100. doi:10.2165/00003495-200363010-00005. PMID 12487623.
  3. Perera, Nirmal; Liolitsa, Danae; Iype, Satheesh; Croxford, Anna; Yassin, Muhammed; Lang, Peter; Ukaegbu, Obioha; van Issum, Christopher (15 August 2012). "Phlebotonics for haemorrhoids". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004322.pub3. ISSN 1465-1858. PMID 22895941.
  4. "Daflon - EurekaSanté par Vidal". EurekaSanté (in French). Retrieved 2018-02-17.
  5. "Notice patient - Daflon 500 mg, comprimé pelliculé - Base de données publique des médicaments". base-donnees-publique.medicaments.gouv.fr (in French). Retrieved 2018-02-17.
  6. "Drug Formulary" (PDF). Hospital Tengku Ampuan Rahimah. 2011.
  7. Norliza (2011-09-14). "Kehamilan & Perubatan". Portal MyHealth (in Malay). Retrieved 2020-01-17.
  8. Martinez-Zapata, Maria José; Vernooij, Robin Wm; Simancas-Racines, Daniel; Uriona Tuma, Sonia Maria; Stein, Airton T.; Moreno Carriles, Rosa Maria M.; Vargas, Emilio; Bonfill Cosp, Xavier (November 3, 2020). "Phlebotonics for venous insufficiency". The Cochrane Database of Systematic Reviews. 11: CD003229. doi:10.1002/14651858.CD003229.pub4. ISSN 1469-493X. PMID 33141449.
  9. Bush, Ronald; Comerota, Anthony; Meissner, Mark; Raffetto, Joseph D.; Hahn, Steven R.; Freeman, Katherine (April 2017). "Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)". Phlebology. 32 (1_suppl): 3–19. doi:10.1177/0268355517692221. ISSN 1758-1125. PMID 28211296.
  10. "Diosmin Uses, Benefits & Dosage - Drugs.com Herbal Database". Drugs.com. Retrieved 2020-01-17.
  11. Publishing, Licorn (2009-11-26). "Benefit of Daflon 500 mg in chronic venous disease-related symptoms". Servier - Phlebolymphology. Retrieved 2020-01-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.